Navigation Links
Dendreon Reports Third Quarter 2010 Financial Results
Date:11/3/2010

eptember 30, 2010 was $347.6 million, or $2.54 per share, which includes a non-cash charge associated with the revaluation of warrants of $142.6 million or $1.04 per share, compared to $187.7 million, or $1.79 per share for the nine months ended September 30, 2009, which included a non-cash charge of $122.8 million or $1.17 per share for warrant revaluation.

As of September 30, 2010, Dendreon had $392.7 million in cash, cash equivalents, and short-term and long-term investments compared to $606.4 million as of December 31, 2009.

Highlights include:

  • Since approval Dendreon has received over 1,000 prescriptions for PROVENGE.
  • Dendreon is on track to make PROVENGE more broadly available in 2011 with the expansion and anticipated licensure of its New Jersey facility in early 2011 and its facilities in Atlanta, Georgia and Orange County, California in mid-2011, for which construction is substantially complete.
  • Dendreon’s revenue guidance for full year 2010 is approximately $46-47 million and for 2011 is expected to be in the range of $350-400 million, with approximately half of that expected to be generated in Q4, based on a standard FDA review period and approval of our new manufacturing facilities.
  • PROVENGE data were presented at the Asian Congress of Urology, European Society of Medical Oncology, and the International Society for Biological Therapy of Cancer.

  • Conference Call InformationDendreon will host a conference call today at 1:30 p.m. PT, 4:30 p.m. ET. To access the live call, dial 1-866-730-5769 (domestic) or +1-857-350-1593 (international); the conference pass code is 35737817. The call will also be audio webcast and will be available from the Company's website at www.dendreon.com under the "Investor/Webcasts and Presentations" section. A recorded rebroadcast will be available for interested parties unable to participate in the live conference call b
    '/>"/>

    SOURCE Dendreon Corporation
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. Dendreon Announces Presentation of PROVENGE Data at the 25th International Society for Biological Therapy of Cancer Annual Meeting
    2. Dendreon Statement on CMS National Coverage Analysis
    3. Dendreon Announces Presentation of PROVENGE Data at the American Urological Association Annual Meeting
    4. Dendreon Presents Updated IMPACT Results Confirming PROVENGE Improves Overall Survival in Patients With Metastatic Castrate-Resistant Prostate Cancer
    5. Dendreon Reports Fourth Quarter and 2009 Year End Financial Results
    6. Dendreon Announces Election of Ian Clark and Pedro Granadillo to Board of Directors
    7. Dendreon Reports PROVENGE Regulatory and Commercialization Progress and Future Pipeline Plans at Analyst Event
    8. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
    9. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
    10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
    11. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/22/2014)... , October 22, 2014 Investor-Edge ... Inc. (NASDAQ: FOLD ), Progenics Pharmaceuticals Inc. ... THLD ), Idera Pharmaceuticals Inc. (NASDAQ: ... Free research on these five companies can be accessed ... 21, 2014, the NASDAQ Composite ended at 4,419.48, up ...
    (Date:10/22/2014)... Calif. , Oct. 22, 2014  Paper ... products, has developed APLS ® Body Guard ... minimizes the spread of bacteria and virus while ... APLS Body Guard Bio features a rugged, external ... edges that create a leak-proof inner chamber that ...
    (Date:10/22/2014)... , October 22, 2014 ... ), a clinical-stage pharmaceutical company focused on ... reported positive top-line clinical results from its Phase ... oral insulin capsules, to treat type 1 diabetes. The ... States under a U.S. Food and ...
    Breaking Medicine Technology:Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 2Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 3Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 4Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 5New, State-Of-The-Art Body Bag Minimizes The Spread Of Bacteria And Virus 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3Oramed Pharmaceuticals Reports Positive Top-Line Data from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 4
    ... 2010 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. ("China-Biotics" or "the ... developer, manufacturer and distributor of probiotics products in ... Company,s research and development department presented at the ... Equipment seminar in Hangzhou, China on November 21st. ...
    ... (OTC Bulletin Board: GOVX ) (the "Company"), an ... Immunodeficiency Virus), has appointed David A. Dodd as Chairman of ... Hildebrand is stepping down as Chairman and will remain on ... a consultant to the Company. Mr. Dodd, age ...
    Cached Medicine Technology:China-Biotics Attended National Probiotics Seminar 2China-Biotics Attended National Probiotics Seminar 3David A. Dodd Appointed Chairman of the Board of GeoVax Labs 2David A. Dodd Appointed Chairman of the Board of GeoVax Labs 3David A. Dodd Appointed Chairman of the Board of GeoVax Labs 4
    (Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. ... cold sores -- herpes simplex -- might increase the risk ... In fact, being a carrier of certain antibodies to the ... found. "The identification of a treatable cause [herpes ... said lead researcher Dr. Hugo Lovheim, an associate professor in ...
    (Date:10/25/2014)... (HealthDay News) -- A large influx of international aid ... avoid tens of thousands of deaths from the widening ... Using a specially designed mathematical model, the ... in just one densely populated county of hard-hit Liberia ... Monrovia. The researchers said that if international aid ...
    (Date:10/25/2014)... FRIDAY, Oct. 24, 2014 (HealthDay News) -- October,s shorter, ... as seasonal affective disorder, according to an expert. ... SAD, may feel overly tired, lack motivation and even ... SAD can lead to suicide, said Dr. Angelos Halaris, ... neurosciences at Loyola University Chicago Stitch School of Medicine. ...
    (Date:10/22/2014)... On October 22, CBS will air an ... both fictional and real. The Charles E Holman ... to advocacy and philanthropy in the battle against Morgellons ... to impart truth and clarity about this misunderstood and ... misconceptions about Morgellons Disease (MD) and most ...
    (Date:10/22/2014)... 2014 For Dr. Iris Hunter, a job ... an extension of her life’s mission. Her extensive experience in ... owner of FirstLight HomeCare, make it clear that Hunter’s mission ... that my work makes a difference in the lives of ... so after much research, I felt ready to start on ...
    Breaking Medicine News(10 mins):Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3Health News:Dr. Iris Hunter to Host Grand Opening of FirstLight HomeCare Tomorrow 2
    ... treatment, study shows , TUESDAY, Jan. 26 (HealthDay News) ... to lower high blood glucose levels caused by corticosteroid ... study has found. , The death rate for septic ... is 60 percent within a short period, according to ...
    ... CHICAGO , Jan. 26 After a week of trial ... $1-million insurance policy on January 20, 2010 , to settle a ... the physician,s failure to timely diagnose bladder cancer. , In Russell v. ... Carmen Russell and Daniel Russell, Jr. , the wife and ...
    ... , International Guidelines Ensure Maximum Protection of Children ... Just weeks after the United Nations General Assembly adopted a resolution ... the international community is struggling to provide appropriate care and protection ... Haiti . The Guidelines are the first international document on ...
    ... NASHVILLE, Tenn. , Jan. 26 Saint ... clinical quality among the top five percent in the nation ... is one of only 269 hospitals that received this distinction ... , The study by HealthGrades, the leading independent healthcare ratings ...
    ... 26 President Obama will need several props to get ... a box of teabags, a paper shredder, and a new "No ... by taking the 2,074 page Senate health bill and stuffing it ... a 20-page bill in plain, honest English," says Betsy McCaughey ...
    ... heart defects (CHD) are the most common birth ... births with one third of affected children requiring ... combined with developmental expectations for independence, behavioral self-regulation ... identification of neurobehavioral symptoms in some survivors. A ...
    Cached Medicine News:Health News:Intensive Insulin Therapy Won't Boost Septic Shock Survival 2Health News:Romanucci & Blandin, LLC, Reaches $1 Million Settlement in Medical Negligence Lawsuit 2Health News:International Community Calls for Prevention of Further Trauma in Haiti 2Health News:International Community Calls for Prevention of Further Trauma in Haiti 3Health News:Saint Thomas Hospital Ranked Top Five Percent in Nation for the Second Consecutive Year According to Quality Study 2Health News:Props for the President at His State of the Union Address 2Health News:Bypass procedure used during infant heart surgery does not impair later neurological outcomes 2
    ... CCR Medical's Articulating Tip Laryngoscopes ... in the Industry. The articulating ... by providing an improved view ... and Fiber Optic styles. We ...
    German Style MacIntosh Fiber Optic Blade Laryngoscopes...
    CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
    CCR Medical fiberoptic green system laryngoscope handles., ,OUTSTANDING PERFORMANCE, QUALITY, AND PRICING MAKE OUR FIBEROPTIC SELECTION MOST ECONOMICAL....
    Medicine Products: